Mass Tort vs. Class Action: Key Differences in U.S. Multi-Plaintiff Litigation

Multi-plaintiff litigation in the United States takes two primary structural forms: class actions and mass torts. Both mechanisms allow large numbers of injured parties to pursue claims against a common defendant, but they differ fundamentally in how plaintiffs are treated, how cases are managed, and how recoveries are calculated and distributed. Understanding these distinctions is essential for anyone navigating the U.S. court system structure or researching large-scale civil litigation outcomes.

Definition and Scope

A class action is a procedural device under Federal Rule of Civil Procedure (FRCP) Rule 23 that allows one or more named plaintiffs to sue on behalf of a defined class of similarly situated individuals. The defining feature is class certification: a federal or state court must certify that the class meets specific criteria before the case proceeds collectively. Under FRCP Rule 23(a), those criteria are numerosity (the class is too large for joinder), commonality (shared legal questions), typicality (named plaintiffs' claims are representative), and adequacy of representation. Class members who do not opt out are bound by the final judgment or settlement, and individual damages are typically uniform or formulaic across the class.

A mass tort, by contrast, treats each plaintiff as an individual litigant with distinct injuries and damages, even though those plaintiffs share a common defendant and a common factual origin — such as a defective pharmaceutical product, a toxic chemical release, or widespread product failure. Mass torts are governed by tort law principles applied on a plaintiff-by-plaintiff basis. Because individual injury profiles vary — different diagnoses, exposures, medical histories, and economic losses — the cases cannot be collapsed into a single claim the way a class action can.

The federal judiciary manages the volume of mass tort cases primarily through Multidistrict Litigation (MDL), authorized under 28 U.S.C. § 1407. The Judicial Panel on Multidistrict Litigation (JPML) consolidates pretrial proceedings in a single district court, improving efficiency while preserving each plaintiff's individual claim. As of the JPML's published statistics, MDL dockets have at times accounted for more than 50% of the entire federal civil caseload (JPML Statistics).

How It Works

Class Action Process:

1. Filing and Class Certification Motion — Named plaintiff(s) file a complaint and move for class certification under FRCP Rule 23 or the applicable state equivalent.
2. Certification Hearing — The court evaluates the Rule 23(a) prerequisites and at least one Rule 23(b) category (e.g., Rule 23(b)(3) for damages classes requiring predominance of common questions).
3. Notice to Class Members — Certified class members receive court-approved notice and, in Rule 23(b)(3) classes, the right to opt out.
4. Discovery and Merits Litigation — Discovery proceeds collectively on class-wide issues.
5. Settlement or Trial — Class-wide settlement requires court approval under FRCP Rule 23(e); any settlement must be found fair, reasonable, and adequate.
6. Distribution — A claims administrator distributes recovery according to a predetermined formula or claims process.

Mass Tort / MDL Process:

1. Individual Filings — Plaintiffs file separate complaints in federal or state courts.
2. MDL Transfer — The JPML transfers federal cases sharing common factual questions to a single transferee court for consolidated pretrial proceedings.
3. Bellwether Trials — The transferee court selects representative cases for early trial. Bellwether verdicts inform settlement negotiations by signaling jury valuation of similar claims.
4. Individual Discovery — Each plaintiff undergoes case-specific depositions and medical record review alongside any consolidated common discovery.
5. Global Settlement or Remand — If a global settlement is reached, plaintiffs receive individualized compensation through a settlement matrix or Special Master–administered allocation. Cases not resolved are remanded to their original districts for trial under 28 U.S.C. § 1407(a).

Common Scenarios

Typical Class Action Categories:
- Consumer fraud claims (uniform overcharges, deceptive billing)
- Securities fraud under the Private Securities Litigation Reform Act of 1995 (15 U.S.C. § 78u-4)
- Employment wage-and-hour violations with standardized pay policies
- Data breach cases with uniform statutory damages (e.g., under state privacy statutes)
- Antitrust price-fixing with common overcharge calculations

Typical Mass Tort Categories:
- Defective pharmaceutical drugs (e.g., cases involving opioid manufacturers consolidated in MDL No. 2804, In re National Prescription Opiate Litigation, N.D. Ohio)
- Medical device failures (e.g., hernia mesh, hip implant defects)
- Toxic chemical or environmental exposure (e.g., PFAS contamination, asbestos)
- Consumer product defects causing physical injury at varying severity levels

The opioid MDL referenced above, involving more than 3,000 consolidated cases at its peak (JPML Docket Records), illustrates how mass tort volume can dwarf typical class actions in case count while still resolving through aggregated negotiation rather than individual trials.

Decision Boundaries

The choice between class action certification and mass tort treatment is not purely strategic — it is governed by legal standards that courts apply to the nature of the claims. The following comparison identifies the operative distinctions:

The predominance requirement is the single most important doctrinal dividing line. Under FRCP Rule 23(b)(3), a damages class can only be certified if common questions "predominate over any questions affecting only individual members" (Rule 23(b)(3)). Mass tort plaintiffs typically fail this test because proof of causation and damages is inherently individualized — the same drug may cause different injuries in different plaintiffs at different doses.

Courts and practitioners also distinguish cases by the burden of proof demands. Where each plaintiff must independently prove medical causation through expert testimony under Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the individual inquiry required defeats class certification and pushes the litigation into mass tort structure.

Punitive damages further complicate class treatment. When punitive exposure depends on the defendant's conduct toward each specific plaintiff, courts have held that a single class-wide punitive damages trial may violate due process (see Philip Morris USA v. Williams, 549 U.S. 346 (2007), addressing the limits of punitive damages awards).

Multidistrict litigation does not eliminate individual claims — it consolidates pretrial efficiency. After MDL proceedings conclude, unresolved cases are remanded to their original districts, preserving each plaintiff's right to an individual trial, a structural guarantee that distinguishes mass torts from class actions where a single verdict binds everyone.

References

• Federal Rules of Civil Procedure, Rule 23 — Cornell Legal Information Institute
• 28 U.S.C. § 1407 — Multidistrict Litigation Statute, U.S. House Office of the Law Revision Counsel
• Judicial Panel on Multidistrict Litigation (JPML) — Official Docket Statistics
• 15 U.S.C. § 78u-4 — Private Securities Litigation Reform Act, U.S. House Office of the Law Revision Counsel
• [Federal